Method and composition for cancer detection in humans
AssigneesNuc Med Inc., University Patents, Inc.
InventorsDavid R. Crockford, Buck A. Rhodes
Life of this patent
Estimating the term…
Abstract
Anti human chorionic gonadotropin (anti-hCG) and/or anti human chorionic gonadotropin- beta subunit (anti-hCG-.beta.) labeled with Technetium-99M are/is administered to a human. The biodistribution of the labeled composition is monitored in order to determine whether the labeled composition accumulates at cancer sites, e.g. tumors that produce human chorionic gonadotropin (hCG), human chorionic gonadotropin-like material, and a compound similar to and/or identical to the beta-chain of chorionic gonadotropin, or mixtures thereof which would bind specifically to anti-hCG and/or anti-hCG-.beta..
Claims12
A composition of matter selected from the group consisting of Technetium-99m labeled anti-human chorionic gonadotropin, Technetium-99m labeled anti-human chorionic gonadotropin-beta and/or mixtures thereof.
The composition comprising Technetium-99m labeled anti-human chorionic gonadotropin.
The composition comprising Technetium-99m labeled humna corionic gonadotropin beta.
A diagnostic kit suitable for forming a composition useful in identifying a cancer cell and/or a malignant tumor which comprise a sterile package containing a protein comprising anti-human chorionic gonadotropin, anti-human chorionic gonadotropin beta or mixtures thereof, and means for mixing the contents of said sterile package with reduced Tc-99m in a physiologically acceptable aqueous solution.
Dependencies are inferred from the claim text.